The downstream target of ATM, CHK2, has been found instead mutated in low rate in several kinds of cancer and in particular in hereditary cancers (CHK2 1100delC protein-truncating mutation confers a twofold increased risk of breast cancer) [50, 51]. Here, ATM is linked to cancer.